|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Src inhibition ameliorates polycystie kidney disease显示文摘 | Sweeney W E Jr von Vigier R O Frost P Avner E D | 2008 | J Am Soe Nephrol2008，19，： | 1 |
| 2 | Effective maintenance treatment of reflux esophagitis with low-dose lansopraole: a randomized,double-blind, placebo-controlled trail显示文摘 | Robinson M Lanza F Avner D | 1996 | Ann Intern Med1996，124，10： | 1 |
| 3 | Pattern of pain management during lumbar puncture in children显示文摘 | Fein D Avner JR Khine H | 2010 | Pediatr Emerg Care2010，26，5： | 1 |
| 4 | Epigenetic switch involved in activation of pioneer factor FOXAl-dependent enhancers显示文摘 | Aurélien A Stéphane Avner Frédéric Percevault | | 0，，04： | 1 |
| 5 | Unique interstitial miRNA signature drives fibrosis in a murine model of autosomal dominant polycystic kidney disease显示文摘AIM To delineate changes in miRNA expression localized to the peri-cystic local microenvironment(PLM) in an orthologous mouse model of autosomal dominant polycystic kidney disease(ADPKD)(mcwPkd1^(nl/nl)).METHODS We profiled miRNA expression in the whole kidney and laser captured microdissection(LCM) samples from PLM in mcwPkd1^(nl/nl)kidneys with Qiagen miScript 384 HC miRNA PCR arrays. The three times points used are:(1) post-natal(PN) day 21, before the development of trichrome-positive areas;(2) PN28, the earliest sign of trichrome staining; and(3) PN42 following the development of progressive fibrosis. PN21 served as appropriate controls and as the reference time point for comparison of miRNA expression profiles.RESULTS LCM samples revealed three temporally upregulated miRNAs [2 to 2.75-fold at PN28 and 2.5 to 4-fold(P ≤ 0.05) at PN42] and four temporally downregulated miRNAs [2 to 2.75 fold at PN28 and 2.75 to 5-fold(P ≤ 0.05) at PN42]. Expression of twenty-six miRNAs showed no change until PN42 [six decreased(2.25 to 3.5-fold)(P ≤ 0.05) and 20 increased(2 to 4-fold)(P ≤ 0.05)]. Many critical miRNA changes seen in the LCM samples from PLM were not seen in the contralateral whole kidney.CONCLUSION Precise sampling with LCM identifies miRNA changes that occur with the initiation and progression of renal interstitial fibrosis(RIF). Identification of the target proteins regulated by these miRNAs will provide new insight into the process of fibrosis and identify unique therapeutic targets to prevent or slow the development and progression of RIF in ADPKD. | Ameya Patil William E Sweeney Jr Cynthia G Pan Ellis D Avner | 2018 | World Journal of Nephrology2018，7，5： | 1 |
| 6 | GATE: a simulation toolkit for PET and SPECT 显示文摘 | S Jan G Santin D Strul S Staelens K Assie D Autret S Avner R Barbier M Bardies P M Bloomfield D Brasse V Breton P Bruyndonckx I Buvat A F Chatziioarmou Y Choi | 2004 | Physics in Medicine and Biology (S0031-9155)2004，49，19： | 1 |
| 7 | Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease显示文摘AIM To investigate the therapeutic potential of tesevatinib(TSV),a unique multi-kinase inhibitor currently in Phase Ⅱ clinical trials for autosomal dominant polycystic kidney disease(ADPKD),in well-defined rodent models of autosomal recessive polycystic kidney disease(ARPKD).METHODS We administered TSV in daily doses of 7.5 and 15 mg/kg per day by I.P.to the well characterized bpk model of polycystic kidney disease starting at postnatal day(PN) 4 through PN21 to assess efficacy and toxicity in neonatal mice during postnatal development and still undergoing renal maturation.We administered TSV by oral gavage in the same doses to the orthologous PCK model(from PN30 to PN90) to assess efficacy and toxicity in animals where developmental processes are complete.The following parameters were assessed:Body weight,total kidney weight;kidney weight to body weight ratios;and morphometric determination of a cystic index and a measure of hepatic disease.Renal function was assessed by:Serum BUN;creatinine;and a 12 h urinary concentrating ability.Validation of reported targets including the level of angiogenesis and inhibition of angiogenesis(active VEGFR2/KDR) was assessed by Western analysis.RESULTS This study demonstrates that:(1) in vivo pharmacological inhibition of multiple kinase cascades with TSV reduced phosphorylation of key mediators of cystogenesis:EGFR,ErbB 2,c-Src and KDR;and(2) this reduction of kinase activity resulted in significant reduction of renal and biliary disease in both bpk and PCK models of ARPKD.The amelioration of disease by TSV was not associated with any apparent toxicity.CONCLUSION The data supports the hypothesis that this multi-kinase inhibitor TSV may provide an effective clinical therapy for human ARPKD. | William E Sweeney Philip Frost Ellis D Avner | 2017 | World Journal of Nephrology2017，6，4： | 1 |
| 8 | Angiogenesis in Wounds Treated by Microdeformational Wound Therapy显示文摘 | Paolo Erba Rei Ogawa Maximilian Ackermann Avner Adini Lino F. Miele Pouya Dastouri Doug Helm Steven J. Mentzer Robert J. D’Amato George F. Murphy Moritz A. Konerding Dennis P. Orgill | 2011 | Annals of Surgery2011，，2： | 1 |
| 9 | Src inhibition ameliorates polycystic kidney disease 显示文摘 | Sweeney W E Jr yon Vigier R O Frost P Avner E D | 2008 | J Am Soc Nephrol2008，19，7： | 1 |
| 10 | Niaudet PI Pediatribc Nephrologyl Lippincott显示文摘 | AVNER E D HARMON W E | 2004 | Williams and Wikins2004，1，8： | 1 |
| 11 | Noble Gases identify the mechanisms of fugitive gas contamination in drinking-water wells overlying the Marcellus and Barnett Shales显示文摘 | THOMAS H D AVNER V ROBERT B J | 2014 | Proceedings of the na- tional Aeaderny of Seienees of the United states of meriea2014，111，14： | 1 |
| 12 | Angiogenesis in Wounds Treated by Microdeformational Wound Therapy显示文摘 | Paolo Erba Rei Ogawa Maximilian Ackermann Avner Adini Lino F. Miele Pouya Dastouri Doug Helm Steven J. Mentzer Robert J. D’Amato George F. Murphy Moritz A. Konerding Dennis P. Orgill | 2011 | Annals of Surgery2011，，2： | 1 |
| 13 | A Theory of Endogenous Institutional Change显示文摘 | AVNER Greif DAVID D Laitin | 2004 | The American Political Science Review2004，，98： | 1 |
| 14 | Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole:A randomized,doubleblind,placebo-controlled trial显示文摘 | Lanza F Avner D | 1996 | Ann Intern Med1996，24，4： | 1 |
| 15 | Pediatric nephrology显示文摘 | Barratt T M Avner E D Harmon W E | 1991 | 4th edition1991，69，1： | 1 |
| 16 | Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis:Summary statement of a first National Institutes of Health/Office of Rare Diseases conference 显示文摘 | Gunay A M Avner E D Bacallao R L | 2006 | J Pediatr2006，149，2： | 1 |
| 17 | Establishing causality in pediatric adverse drug reactions: use of the Naranjo probability scale 显示文摘 | Avner M Finkelstein Y Hackam D | 2007 | Paediatr Drugs2007，9，4： | 1 |
| 18 | Establishing causality in pediatric adverse drug reactions: use of the Naranjo probability scale 显示文摘 | Avner M Finkelstein Y Hackam D | 2007 | Paediatr Drugs2007，9，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员